B. Kim Lee Sim, Phd
President, Chief Scientific Officer
Life Science
Protein Potential
United States of America
Biography
B. Kim Lee Sim Ph.D over 25 years of experience in vaccine development and research. Dr. Sim did her undergraduate (BS, Honors, First Class) and graduate studies (MS, PhD) at the University of Malaya, Kuala Lumpur, Malaysia. After a post doctoral fellowship in molecular biology at Harvard School of Public Health, she was a research scientist at the Walter Reed Army Institute of Research and an adjunct faculty at the Uniformed Services University of Health Sciences, a research assistant professor at Johns Hopkins School of Public Health, and an Expert at the National Institute of Allergy and Infectious Diseases, NIH. In 1993 Dr. Sim left the NIH to join a start up company, EntreMed Inc, as Research Director of Molecular Biology, and in 1999 she was appointed Vice President Pre-Clinical Research and Development. At EntreMed Dr. Sim established and managed the development program for anti-angiogenic proteins for the therapy of cancer, and developed the process that led to the cGMP manufacture of tens of kilograms of recombinant Angiostatin and Endostatin, two anti-angiogenic proteins that entered Phase II clinical trials. Dr. Sim is also the Executive Vice President of Process Development and Manufacturing at Sanaria Inc., a company developing a live attenuated whole organism malaria vaccine (www.sanaria.com). Dr. Sim is a Board Member of Sanaria Inc. Dr. Sim has published more than 85 scientific papers, and has 7 issued and more than 15 pending patents.
Research Interest
Purified recombinant proteins and DNA plasmids that express these proteins are at the core of modern biologics research, development, and products, and the discovery and development of small molecule drugs. Rapid translation of the enormous numbers of discoveries in genomics, proteomics and high throughput screening into potential commercial products such as drugs, vaccines, and diagnostics requires a robust, high quality protein development and production process that takes molecules from discovery through initiation of clinical trials.
